Document is current
Any future updates will be listed below
-
Authors
Urabe, Makiko
Ikezawa, Kenji
Seiki, Yusuke
Watsuji, Ko
Kawamoto, Yasuharu
Hirao, Takeru
Kai, Yugo
Takada, Ryoji
Yamai, Takuo
Mukai, Kaori
Nakabori, Tasuku
Uehara, Hiroyuki
Nagata, Shigenori
Ohkawa, Kazuyoshi
- License Information
-
More Information
Article History
Received: 23 January 2024
Accepted: 12 September 2024
First Online: 20 September 2024
Competing interests
: Ikezawa reports honoraria for lectures from Taiho Pharmaceutical, Yakult Honsha, Ono Pharmaceutical, MSD, Myriad Genetics, ASAHI KASEI PHARMA, Nihon Servier, AstraZeneca and Incyte Biosciences Japan, and research funding from ASKA Pharmaceutical. Takada reports honoraria for lectures from Taiho Pharmaceutical, Hisamitsu Pharmaceutical, Novartis, Myriad Genetics and TEIJIN PHARMA. Yamai reports honoraria for lectures from Taiho Pharmaceutical and Yakult Honsha. Ohkawa reports honoraria for lectures from Eisai, Chugai Pharmaceutical, Yakult Honsha, Incyte Biosciences Japan, Takeda, Gilead, AstraZeneca and Hisamitsu, and research grants from Towa Pharmaceutical and Sumitomo Chemical. The other authors have no conflict of interest.
